title: Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial.
abstract: To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.
  
  
  
  This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m(2) ) consumed an energy-reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O-R, and they consumed the energy-reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24-h recall was performed, along with measurements of anthropometric and serum biochemical parameters.
  
  
  
  A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of -6.82 kg (95% CI -8.37 to -5.26) was observed in the O-R group compared with -3.50 kg (-5.05 to -1.95, P = 0.021) in the placebo group. In contrast, the -6.02 kg (-7.68 to -4.36) orlistat and -4.68 kg (-6.64 to -2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O-R combination.
  
  
  
  The O-R combination was the most effective weight loss treatment.
authors.affiliation: Instituto Biosen A.C, Mexico D.F., Mexico.
authors.forename: María Angélica
authors.initials: MA
authors.lastname: Arzola-Paniagua
authors.affiliation: Instituto Biosen A.C, Mexico D.F., Mexico.
authors.forename: Enrique Raúl
authors.initials: ER
authors.lastname: García-Salgado López
authors.affiliation: Departamento de Nutricion, Centro de Diseño y Planeación en Investigación Médica S.C, Guadalajara, Jalisco, Mexico.
authors.forename: Cesar G
authors.initials: CG
authors.lastname: Calvo-Vargas
authors.affiliation: Departmento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico D.F., Mexico.
authors.forename: Martha
authors.initials: M
authors.lastname: Guevara-Cruz
mesh_terms: D000328:Adult; D000368:Aged; D000886:Anthropometry; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D031204:Caloric Restriction; D004032:Diet; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D002149:Energy Intake / Q000187:drug effects; D005260:Female; D006801:Humans; D007783:Lactones / Q000008:administration & dosage* / Q000627:therapeutic use; D020738:Leptin / Q000097:blood; D008297:Male; D008800:Mexico; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D000077403:Orlistat; D010919:Placebos; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D015431:Weight Loss
chemical_list: D019440:Anti-Obesity Agents; D007783:Lactones; D020738:Leptin; D010919:Placebos; D013267:Stilbenes; D014280:Triglycerides; D000077403:Orlistat; D000077185:Resveratrol